Inborn Errors Of Metabolism Stocks List

Recent Signals

Date Stock Signal Type
2021-05-07 AGIO Cup with Handle Other
2021-05-07 AGIO NR7 Range Contraction
2021-05-07 AGIO Bollinger Band Squeeze Range Contraction
2021-05-07 AGLE Narrow Range Bar Range Contraction
2021-05-07 AGLE NR7 Range Contraction
2021-05-07 BMRN Stochastic Reached Oversold Weakness
2021-05-07 BMRN 20 DMA Resistance Bearish
2021-05-07 BMRN Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-05-07 BMRN Bollinger Band Squeeze Range Contraction
2021-05-07 BMRN Fell Below 50 DMA Bearish
2021-05-07 FOLD NR7 Range Contraction
2021-05-07 FOLD Narrow Range Bar Range Contraction
2021-05-07 FOLD Bollinger Band Squeeze Range Contraction
2021-05-07 NTLA 50 DMA Resistance Bearish
2021-05-07 SYBX Pocket Pivot Bullish Swing Setup
2021-05-07 SYBX Narrow Range Bar Range Contraction
2021-05-07 SYBX NR7 Range Contraction

Recent News for Inborn Errors Of Metabolism Stocks

Date Stock Title
May 7 NTLA Intellia Therapeutics, Inc. (NTLA) Q1 2021 Earnings Call Transcript
May 7 FOLD Amicus Therapeutics to Present at Upcoming Investor Conferences in May 2021
May 6 NTLA Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q1 2021 Results - Earnings Call Transcript
May 6 NTLA Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates
May 6 AGLE Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency
May 6 NTLA Intellia's Q1 net loss widens as CRISPR biotech misses earnings expectations
May 6 SYBX Synlogic Announces First Quarter 2021 Conference Call & Webcast
May 6 NTLA Intellia Therapeutics EPS misses by $0.04, misses on revenue
May 6 NTLA Intellia Therapeutics Announces First Quarter 2021 Financial Results
May 6 FOLD Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development
May 6 NTLA Intellia Therapeutics, Inc. to Host Earnings Call
May 5 FOLD Is Amicus Therapeutics Inc. (FOLD) A Smart Long-Term Buy?
May 5 NTLA Intellia Therapeutics Q1 2021 Earnings Preview
May 5 FOLD Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 24th Annual Meeting
May 4 BMRN Was The Smart Money Right About BioMarin (BMRN)?
May 4 NTLA Intellia and Sangamo preferred as RBC extends gene editing coverage
May 3 FOLD Amicus Therapeutics (FOLD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
May 3 AGLE Aeglea completes patient randomization in late-stage pegzilarginase trial
May 3 FOLD Amicus Therapeutics Concludes Pre-BLA Meeting With FDA For AT-GAA In Pompe Disease
May 3 AGLE Aeglea BioTherapeutics Completes Patient Randomization for PEACE, its Pivotal Phase 3 Clinical Trial of Pegzilarginase for the Treatment of Arginase 1 Deficiency
Related Industries: Biotechnology